Australia’s Proposed Gene Technology Reforms: Implications for Cell and Gene Therapy Clinical Trials

Australia is progressing substantial reforms to the way dealings with genetically modified organisms are regulated under the National Gene Technology Scheme.

For sponsors of cell and gene therapy trials, the proposed changes are important. They would introduce a more risk-tiered framework, including new GMO Permit pathways and a non-notifiable dealing class for certain genetically modified human somatic-cell therapies.

The reforms are not yet law. The current Gene Technology Act 2000 and Gene Technology Regulations 2001 remain in force while the proposed legislative package continues to develop. Sponsors need to plan against the requirements that apply today while understanding how the proposed framework could affect programmes extending beyond commencement.

1. The Current Australian Regulatory Framework

Dealings with genetically modified organisms are regulated under the Gene Technology Act 2000 (Cth) and Gene Technology Regulations 2001, administered by the Gene Technology Regulator through the Office of the Gene Technology Regulator (OGTR).

The primary object of the Act is to protect the health and safety of people and the environment by identifying and managing risks arising from gene technology. The Commonwealth legislation forms part of a nationally consistent scheme and operates alongside other Commonwealth and State regulatory regimes.

What Is a “Dealing” with a GMO?

The concept of a dealing is broad. It includes conducting experiments with a GMO, making or manufacturing it, breeding or propagating it, growing or culturing it, importing it, transporting it, disposing of it and certain associated possession, supply or use.

For a clinical-trial sponsor, the assessment therefore needs to look beyond administration of the investigational product. The full Australian handling chain may be relevant, including importation, storage, preparation, administration, sample handling, transport and waste.

Cell Therapy Is Not Automatically a GMO Dealing

The TGA uses “advanced therapies” as an umbrella term that includes gene therapies, gene-modified cell therapies and certain Class 3 or 4 cell and tissue therapies. The Gene Technology Act has a different scope: it regulates dealings with GMOs rather than therapeutic products simply because they fall within the TGA’s advanced-therapy terminology.

Does the product or proposed Australian activity involve a GMO regulated under the Gene Technology Act?

If the cells have not been genetically modified and no other GMO dealing is involved, the Act is not engaged merely because the investigational product is a cell therapy. TGA, HREC and institutional requirements may still apply.

Current Pathways for GMO Clinical Trials

Where a trial does involve a GMO, it will commonly require either a DNIR licence for dealings not involving intentional release, or a DIR licence for dealings involving intentional release. The current framework also includes exempt dealings, notifiable low risk dealings and the GMO Register.

Intentional release may arise from the mode of administration itself or from shedding, excretion or transmission of viable GMO from participants. Administration in a controlled clinical setting does not, by itself, determine the classification.

2. Cell Therapies Under the Current Framework

An important exception already exists for certain genetically modified human somatic-cell therapies. OGTR guidance states that introduction of genetically modified human somatic cells, including re-introduction of genetically modified autologous cells, does not require a GMO licence where specified criteria are satisfied.

In broad terms, the cells must not be capable of secreting or producing infectious agents as a result of the genetic modification. Where a viral vector was used, the cells must have been tested and found not to contain viruses likely to recombine with the modified nucleic acid, and the vector must no longer be present in the GM somatic cells.

Dealings satisfying these criteria are treated as exempt dealings. They remain regulated under the Act but do not require specific authorisation from the Regulator. Once qualifying GM somatic cells have been introduced into the person, OGTR guidance states that those cells cease to be regulated under the Act.

This is relevant to some ex vivo genetically modified cell therapies. A sponsor should not assume that every CAR-T or other GM somatic-cell product requires a DNIR or DIR licence.

Administration and Manufacturing Are Different Dealings

An administration dealing may be exempt while other dealings involving the same product are not. Where GM somatic cells are produced in Australia, the production process must itself be appropriately authorised. For an international sponsor, assessment should therefore consider where cells are manufactured, where genetic modification occurs, what material is imported and what activities occur at Australian sites.

Current Statutory Licence Decision Periods

These periods should not be treated as the complete elapsed time from lodgement to decision. They exclude specified periods, including time spent awaiting requested information. Based on practical experience with OGTR clinical-trial submissions, sponsors should also allow approximately two to three weeks after lodgement for initial review and determination of whether an application is acceptable for formal assessment. This is a practical planning allowance, not a statutory timeframe or published OGTR service standard.

The Role of the Institutional Biosafety Committee

For current GMO licence applications, IBC review is an important part of the process. OGTR states that licence applications must be reviewed and endorsed by an appropriately constituted Institutional Biosafety Committee before submission. This should be distinguished from an exempt dealing, for which no specific authorisation from the Regulator is required.

Whether or not an OGTR licence is required, the broader Australian clinical-trial framework continues to apply. Unapproved therapeutic goods may proceed through the TGA’s CTN or CTA scheme as applicable, and HREC and institutional requirements remain relevant. An OGTR exemption is not an exemption from Australian clinical-trial regulation generally.

3. The Legal Architecture of the Proposed Reforms

The proposed reforms would introduce a more risk-tiered authorisation framework comprising GMO licences, GMO permits, notifiable dealings, non-notifiable dealings and the GMO Register. Dealings prescribed as designated dealings would remain subject to full licensing.

The eventual eligibility of a trial will not be determined by a single document:

• The Act would establish the principal statutory architecture, including authorisation pathways and the Regulator’s powers.
• The Regulations would define classes of dealings and important boundaries.
• Rules made by the Regulator would contain further technical requirements, restrictions and conditions.
• Guidance and implementation materials would support practical application of the enacted framework.

The Department has confirmed that proposed Rules will be developed separately from the Amendment Regulations and will themselves be subject to consultation. Some of the technical criteria most important to therapeutic sponsors therefore remain unresolved.

4. Proposed Pathways Relevant to Therapeutic Products

Class P2 — Clinical Trials Involving a Therapeutic GMO

P2 is the proposed permit class most directly relevant to clinical trials involving therapeutic GMOs. The consultation material indicates that it would apply where administration occurs in a clinical setting, the GMO is of a form or type previously authorised for a clinical trial, the GMO is replication defective or unable to form a virion, the modifications do not increase its capacity to cause harm and the dealing is not designated.

The concept of a “form or type previously authorised” may prove to be one of the most important practical boundaries. It remains unclear whether previous authorisation will be assessed principally by platform, vector, serotype, construct or individual product, and how a new transgene, promoter or payload will affect eligibility. Until the final Regulations and Rules are available, P2 should be treated as a proposed pathway with high-level criteria, not an established pathway for a particular platform.

Class P3 — Certain Special Access Scheme Uses

P3 concerns specified administration of a GMO for therapeutic use under the TGA’s Special Access Scheme Category A or B, together with proposed risk-group and biosecurity criteria. It is separate from the CTN and CTA pathways used for clinical trials.

Class P4 — GM Somatic Cells Containing Residual Infectious Viral Vector

P4 would cover introduction of genetically modified human somatic cells where the cells contain residual infectious viral vector, provided the dealing is not designated. The Rules would prescribe conditions, potentially drawing on controls used in previous clinical-trial licences.

NND4 — A Proposed Non-Notifiable Pathway

NND4 is proposed for introduction of genetically modified human somatic cells into a human for somatic-cell therapies, with CAR-T given as the consultation example. The class is framed more broadly than CAR-T alone.

The proposal excludes, among other things, dealings involving residual infectious viral vector, cells capable of giving rise to an infectious agent as a result of the modification, specified viral-recombination circumstances or designated dealings. The Rules may further restrict the class.

NND4 is described as a new class, not simply a restatement of current exempt-dealing criteria. Sponsors should not assume that an existing exemption assessment will automatically map onto NND4, or that a product requiring a licence today will necessarily fall within the future non-notifiable pathway.

5. What Could Change for Different Cell-Therapy Programmes?

The reforms should not be reduced to a simple story that DNIR and DIR licences will be replaced by a 30-day permit. Some GM cell therapies may continue in a lower-burden pathway; others may become eligible for a permit. The answer depends on the product and the dealings involved.

6. What the Proposed 30-Business-Day Period Means — and Does Not Mean

For an eligible P2, P3 or P4 dealing, the period could represent a substantial reduction from current licence decision periods. But it appears in proposed reform material, does not establish that a particular product will qualify, does not guarantee that a permit will be issued and does not replace TGA, HREC or institutional requirements. Time may also be excluded where further information is requested.

The period does not apply to an NND4 dealing because a non-notifiable dealing would not require a permit application. The future role of IBC review will depend on the enacted Regulations, Regulator’s Rules and conditions for the relevant pathway.

7. Transitional Issues Remain Unresolved

Transition is one of the most important areas still to be settled. The 2024 exposure draft did not resolve the issue, and stakeholders have sought greater clarity about how the reforms would apply to clinical and therapeutic settings.

Questions include the treatment of existing DNIR and DIR licences, pending applications, current exempt dealings, existing IBC assessments and NLRDs, licence variations, additional sites and trials that continue across commencement.

For cell-therapy sponsors, a particular issue is what will happen to dealings currently treated as exempt when the new non-notifiable framework begins. The consultation material contemplates commencement approximately 12 months after passage of the Amendment Bill, but that remains a proposal rather than a confirmed date.

Sponsors should not defer an otherwise necessary current regulatory strategy simply because a more favourable future classification may become available.

8. Different Regulatory Objectives for Therapeutic GMOs

The reforms also sit against an important difference in regulatory purpose. The Therapeutic Goods Act 1989 expressly recognises the timely availability of therapeutic goods as one of its objects, alongside quality, safety and efficacy.

The Gene Technology Act 2000 has a different primary object: protecting people and the environment by identifying and managing risks arising from gene technology. It also requires an efficient and effective system operating alongside other regulatory schemes, but the statutory test for a GMO licence is principally concerned with whether risks can be managed.

These objectives are not legally inconsistent, but they can create practical tension. A product may progress through the therapeutic-goods and clinical-trial framework while still requiring a separate gene-technology authorisation focused on environmental and biosafety risk.

9. Practical Position for Sponsors

For an Australian cell or gene therapy programme, the practical steps are:

• Check whether the Act applies. Distinguish a non-genetically modified cell therapy from a product or activity involving a GMO.
• Map the Australian dealings. Consider importation, manufacturing, preparation, storage, administration, participant samples, transport and disposal.
• Check the current exemption. For GM somatic-cell products, do not assume a licence is needed without assessing the criteria.
• Separate administration from manufacturing. Exempt administration does not automatically make upstream activity exempt.
• Determine the current licence pathway if needed. Depending on the dealings, a DNIR or DIR licence may be relevant.
• Consider the proposed direction separately. Assess possible P2, P3, P4 or NND4 relevance without treating a proposal as current law.
• Identify evidence early. Vector characteristics, replication competence, residual-vector testing, recombination, shedding, environmental exposure and waste controls may matter.
• Plan workstreams together. Coordinate OGTR and IBC requirements with TGA, HREC and site start-up.
• Watch the whole reform package. The Bill alone will not determine the final pathways; the Regulations, Rules and transitional provisions will also matter.

The central discipline is to keep three questions separate:

What applies now? What does the current law require for this product and dealing?

What is proposed? How might the proposed framework alter that pathway?

What is still unknown? Which technical criteria, conditions and transitional arrangements remain unresolved?

Current Status

As at 26 August 2026, the proposed reforms remain under development. The Amendment Bill has not been introduced, the final technical criteria and Regulator’s Rules are not available, and the current Gene Technology Act 2000, Regulations and authorisation framework remain in force.